📣 VC round data is live. Check it out!

AnteoTech Valuation Multiples

Discover revenue and EBITDA valuation multiples for AnteoTech and similar public comparables like Finemedix, IMD International Medical, Harvard Apparatus, CS Diagnostics and more.

AnteoTech Overview

About AnteoTech

AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its key areas are the Energy and Life Science Division. The company is developing four products named AnteoX, Ultranode, AnteoBind NXT, and AnteoBind these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the AnteoTech IP.


Founded

1995

HQ

Australia

Employees

40

Financials (LTM)

Revenue: $652K
EBITDA: ($2M)

EV

$28M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

AnteoTech Financials

AnteoTech reported last 12-month revenue of $652K and negative EBITDA of ($2M).

In the same LTM period, AnteoTech generated ($2M) in EBITDA losses and had net loss of ($3M).

Revenue (LTM)


AnteoTech P&L

In the most recent fiscal year, AnteoTech reported revenue of $698K and EBITDA of ($4M).

AnteoTech is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (529%), and net margin of (631%).

See analyst estimates for AnteoTech
LTMLast FY202320242025202620272028
Revenue$652K$698K$298K$515K$675K
Gross Profit$698K$298K$515K$698K
Gross Margin100%100%100%103%
EBITDA($2M)($4M)($9M)($7M)($4M)
EBITDA Margin(376%)(529%)(2915%)(1389%)(600%)
EBIT Margin(487%)(631%)(3162%)(1540%)(714%)
Net Profit($3M)($4M)($8M)($6M)($4M)
Net Margin(478%)(631%)(2607%)(1094%)(575%)

Financial data powered by Morningstar, Inc.

AnteoTech Stock Performance

AnteoTech has current market cap of $28M, and enterprise value of $28M.

Market Cap Evolution


AnteoTech's stock price is $0.01.

AnteoTech share price increased by 31.4% in the last 30 days, and by 64.8% in the last year.

See more trading valuation data for AnteoTech
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$28M$28M7.9%31.4%8.8%64.8%$-0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

AnteoTech Valuation Multiples

AnteoTech trades at 43.0x EV/Revenue multiple, and (11.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for AnteoTech

EV / Revenue (LTM)


AnteoTech Financial Valuation Multiples

As of May 9, 2026, AnteoTech has market cap of $28M and EV of $28M.

AnteoTech has a P/E ratio of (8.9x).

LTMLast FY202320242025202620272028
EV/Revenue43.0x40.1x94.0x54.4x41.5x
EV/EBITDA(11.4x)(7.6x)(3.2x)(3.9x)(6.9x)
EV/EBIT(8.8x)(6.3x)(3.0x)(3.5x)(5.8x)
EV/Gross Profit40.1x94.0x54.4x40.1x
P/E(8.9x)(6.3x)(3.6x)(4.9x)(7.2x)
EV/FCF(6.4x)(4.8x)(5.7x)(6.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified AnteoTech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

AnteoTech Margins & Growth Rates

AnteoTech decreased revenue by 7% and EBITDA by 39% in the last fiscal year.

In the most recent fiscal year, AnteoTech reported gross margin of 100%, EBITDA margin of (529%), and net margin of (631%).

See estimated margins and future growth rates for AnteoTech

AnteoTech Margins

Last FY202420252026202720282029
Gross Margin100%100%103%
EBITDA Margin(529%)(1389%)(600%)(95%)
EBIT Margin(631%)(1540%)(714%)(146%)
Net Margin(631%)(1094%)(575%)(146%)
FCF Margin(624%)(953%)(646%)

AnteoTech Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(7%)73%31%98%
Gross Profit Growth73%36%
EBITDA Growth(39%)(18%)(43%)(69%)
EBIT Growth(33%)(16%)(39%)(59%)
Net Profit Growth(34%)(27%)(31%)(50%)
FCF Growth(17%)(11%)

Data powered by FactSet, Inc. and Morningstar, Inc.

AnteoTech Operational KPIs

AnteoTech's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

AnteoTech's Rule of 40 is 4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

AnteoTech's Rule of X is 152% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for AnteoTech
LTMLast FY202320242025202620272028
Rule of 40(195%)4%
Bessemer Rule of X77%152%
Revenue per Employee$0.0M
Opex per Employee$0.2M
S&M Expenses to Revenue66%284%87%68%
G&A Expenses to Revenue763%1264%889%789%
R&D Expenses to Revenue64%87%67%
Opex to Revenue1055%3262%1640%1091%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

AnteoTech Competitors

AnteoTech competitors include Finemedix, IMD International Medical, Harvard Apparatus, CS Diagnostics, Vivos, Harvard Bioscience, Polyrizon, Implanet, European Medical Solutions and BrainCool.

Most AnteoTech public comparables operate across Life Sciences Tools, Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Finemedix4.0x(25.3x)
IMD International Medical0.4x5.5x
Harvard Apparatus35.8x(3.7x)
CS Diagnostics356.9x
Vivos422.9x(9.1x)
Harvard Bioscience0.8x0.8x8.2x8.0x
Polyrizon(5.8x)
Implanet2.4x(7.9x)

This data is available for Pro users. Sign up to see all AnteoTech competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About AnteoTech

When was AnteoTech founded?AnteoTech was founded in 1995.
Where is AnteoTech headquartered?AnteoTech is headquartered in Australia.
How many employees does AnteoTech have?As of today, AnteoTech has over 40 employees.
Is AnteoTech publicly listed?Yes, AnteoTech is a public company listed on Australian Securities Exchange.
What is the stock symbol of AnteoTech?AnteoTech trades under ADO ticker.
When did AnteoTech go public?AnteoTech went public in 2000.
Who are competitors of AnteoTech?AnteoTech main competitors include Finemedix, IMD International Medical, Harvard Apparatus, CS Diagnostics, Vivos, Harvard Bioscience, Polyrizon, Implanet, European Medical Solutions, BrainCool.
What is the current market cap of AnteoTech?AnteoTech's current market cap is $28M.
What is the current revenue of AnteoTech?AnteoTech's last 12 months revenue is $652K.
What is the current revenue growth of AnteoTech?AnteoTech revenue growth (NTM/LTM) is 181%.
What is the current EV/Revenue multiple of AnteoTech?Current revenue multiple of AnteoTech is 43.0x.
Is AnteoTech profitable?No, AnteoTech is not profitable.
What is the current EBITDA of AnteoTech?AnteoTech has negative EBITDA and is not profitable.
What is AnteoTech's EBITDA margin?AnteoTech's last 12 months EBITDA margin is (376%).
What is the current EV/EBITDA multiple of AnteoTech?Current EBITDA multiple of AnteoTech is (11.4x).
How many companies AnteoTech has acquired to date?AnteoTech hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies AnteoTech has invested to date?AnteoTech hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to AnteoTech

Lists including AnteoTech

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial